Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) share value has been down for the past one year. As a result, investors have lost the stock value in the last twelve months. But, ACAD is a well-known company that has given profits to many investors previously. Due to the Coronavirus pandemic, ACAD company operations were deeply affected and its share price dropped almost by 113% in the past three years. However, it is good news for those who already bought the ACAD stocks as ACAD share price is up again by 33% after the last quarter results evaluation!
The Biopharmaceutical Company, NASDAQ: ACAD at https://www.webull.com/quote/nasdaq-acad wasn’t profitable for investors in the last twelve months. It mainly focuses on the development and commercialization of small molecule drugs that are used to treat different central nervous system disorders. Currently, the company is working on the development of Pimavanserin as an adjunctive treatment for schizophrenia. It is now going through phase 3 clinical trials. ACAD Beta Value (5Y monthly) is now 1.80 which measures the systematic risks of ACAD in the stock market.
ACAD current stock price and last quarter earnings report:
ACAD’s stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then its stock value increased by 49.1% and is trading now at $54.97(as of 18th July 2020).
NASDAQ: ACAD earned $90.07 million during the quarter, compared to the consensus estimate of $90.76 million. ACAD had a negative net margin of 64.99% and a negative return on equity of 39.40%. Its revenue for the quarter was up 43.1% on a year over year basis. The next earning date is scheduled to release on Thursday, July 29rd 2020.
The company has a market capitalization of $8.57 billion and generates $339.08 million in revenue each year. As of the most recent Fiscal, this year, the company earnings per share are $1.60 and Net income (Profit) is $235.26 million. Research analysts have issued 1-year price targets which range from $31.00 to $72.00. On average, NASDAQ: ACAD expects the share price to reach $58.56 in the next year which suggests an increase of 6.5%from the stock current price. Its Forward P/E ratio is -90.11.
What can happen next?
NASDAQ: ACAD has a strong correlation between the share price and the EPS (earnings per share). Arguably, company revenue will see better hikes in the future. However, marketers are not expecting good top-line growth as ACAD’s revenue growth rate was 53% per year, for the last three years. Meanwhile, its share price performance was consistent at 29% for the last three years. Marketers now need to pay attention to its strong revenue growth! You can open a brokerage account for stock trading. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.